Disparities in Human Papillomavirus Vaccine Completion Among Vaccine Initiators

被引:50
作者
Chou, Betty [1 ]
Krill, Lauren S.
Horton, Bernice B.
Barat, Christopher E.
Trimble, Cornelia L.
机构
[1] Johns Hopkins Bayview Med Ctr, Dept Obstet & Gynecol, Baltimore, MD 21224 USA
关键词
UNITED-STATES; PREVENTION; INFECTION; BURDEN; WOMEN;
D O I
10.1097/AOG.0b013e318220ebf3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: To estimate rates of completing the full three-dose prophylactic human papillomavirus (HPV) vaccination regimen in patients who initiated the series and to identify variables associated with not completing vaccination. METHODS: This single-institution review identified all patients initiating HPV vaccination at one of four affiliated clinics between January 2007 and June 2008. Vaccination "completers" were defined as patients who had completed all three vaccinations within 12 months of initiating the vaccination series. Logistic regression was used to identify factors associated with vaccine completion. Variables analyzed included age, type of insurance (private compared with public), practice location (urban compared with suburban), practice type (pediatrics, gynecology, or family practice), and race or ethnicity (white or African American and Hispanic). RESULTS: Of the 1,413 girls and young women who initiated HPV vaccination, 469 (33.2%) completed the vaccine series. Overall, private insurances (odds ratio 1.87, 95% confidence interval 1.26-2.76) and suburban practice locations (odds ratio 1.44, 95% confidence interval 1.04-1.98) were associated with higher vaccine completion rates. African American race was associated with lower completion rates (odds ratio 0.50, 95% confidence interval 0.38-0.65). In multivariable analyses, the combination of younger age (11-17 years) and urban practice location was associated with very low likelihood of completing HPV vaccination (22%; P=.023). CONCLUSION: The HPV vaccine completion rate is low. When resources are limited, disparities in HPV vaccine completion should be considered when developing programs to improve vaccine utilization. Urban girls and young women should be targeted as an at-risk population. (Obstet Gynecol 2011;118:14-20) DOI: 10.1097/AOG.0b013e318220ebf3
引用
收藏
页码:14 / 20
页数:7
相关论文
共 30 条
[21]   Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992-2003 [J].
McDougall, Jean A. ;
Madeleine, Margaret M. ;
Daling, Janet R. ;
Li, Christopher I. .
CANCER CAUSES & CONTROL, 2007, 18 (10) :1175-1186
[22]   The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination [J].
Monk, Bradley J. ;
Herzog, Thomas J. .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2007, 197 (04) :337-339
[23]   Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: Risk factors and differences, by phylogenetic type [J].
Moscicki, AB ;
Ellenberg, JH ;
Farhat, S ;
Xu, JH .
JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (01) :37-45
[24]   HPV in the etiology of human cancer [J].
Munoz, Nubia ;
Castellsague, Xavier ;
de Gonzalez, Amy Berrington ;
Gissmann, Lutz .
VACCINE, 2006, 24 :1-10
[25]   Factors Associated With Completion of the Human Papillomavirus Vaccine Series [J].
Neubrand, Tara P. L. ;
Breitkopf, Carmen Radecki ;
Rupp, Richard ;
Breitkopf, Daniel ;
Rosenthal, Susan L. .
CLINICAL PEDIATRICS, 2009, 48 (09) :966-969
[26]   A critique of criteria for evaluating vaccines for inclusion in mandatory school immunization programs [J].
Opel, Douglas J. ;
Diekema, Douglas S. ;
Marcuse, Edgar K. .
PEDIATRICS, 2008, 122 (02) :E504-E510
[27]   Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women:: an interim analysis of a phase III double-blind, randomised controlled trial [J].
Paavonen, Jorma ;
Jenkins, David ;
Bosch, F. Xavier ;
Naud, Paulo ;
Salmeron, Jorge ;
Wheeler, Cosette M. ;
Chow, Song-Nan ;
Apter, Dan L. ;
Kitchener, Henry C. ;
Castellsague, Xavier ;
de Carvalho, Newton S. ;
Skinner, S. Rachel ;
Harper, Diane M. ;
Hedrick, James A. ;
Jaisamrarn, Unnop ;
Limson, Genara A. M. ;
Dionne, Marc ;
Quint, Wim ;
Spiessens, Bart ;
Peeters, Pascal ;
Struyf, Frank ;
Wieting, Susan L. ;
Lehtinen, Matti O. ;
Dubin, Gary .
LANCET, 2007, 369 (9580) :2161-2170
[28]   The predicted impact of vaccination on human papillomavirus infections in Australia [J].
Smith, Megan A. ;
Canfell, Karen ;
Brotherton, Julia M. L. ;
Lew, Jie-Bin ;
Barnabas, Ruanne V. .
INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (08) :1854-1863
[29]  
Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
[30]  
ANN HPV VACCINE UPTA